Evidence map›Paper›PMID 42305208›Full record

ArticleACS medicinal chemistry letters2026

Discovery of 2H-Pyrrolo[3,4‑

Eric Therrien, Shulu Feng, Katherine Amberg-Johnson, Nadim Shaikh, Pradeep Patil, Sarmistha Majumdar, Nikita Abraham, Daniel Eiler, Steffen Kutter, Steven K Albanese and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eric TherrienSchrödinger Inc., New York, New York, 10036, United States.ORCID https://orcid.org/0000-0003-3306-9162
Shulu FengSchrödinger Inc., New York, New York, 10036, United States.
Katherine Amberg-JohnsonSchrödinger Inc., New York, New York, 10036, United States.
Nadim ShaikhSchrödinger Inc., Hyderabad, 500081, Telangana, India.
Pradeep PatilSchrödinger Inc., Hyderabad, 500081, Telangana, India.
Sarmistha MajumdarSchrödinger Inc., Hyderabad, 500081, Telangana, India.
Nikita AbrahamSchrödinger Inc., Hyderabad, 500081, Telangana, India.
Daniel EilerSchrödinger Inc., Framingham, Massachusetts 01702, United States.
Steffen KutterSchrödinger Inc., Framingham, Massachusetts 01702, United States.
Steven K AlbaneseSchrödinger Inc., New York, New York, 10036, United States.
Susanta HaldarSchrödinger Inc., Hyderabad, 500081, Telangana, India.
Kyle G KroeckSchrödinger Inc., Framingham, Massachusetts 01702, United States.
Christian AtsrikuSchrödinger Inc., New York, New York, 10036, United States.
Aleksey I GerasyutoSchrödinger Inc., New York, New York, 10036, United States.ORCID https://orcid.org/0009-0001-2696-7207
Adam M LevinsonSchrödinger Inc., New York, New York, 10036, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical emergence of diverse c-MET mutations with resistance to approved inhibitors has created an urgent demand for next-generation inhibitors with efficacy against c-MET-resistant mutations while maintaining c-MET wild-type (WT) potency, selectivity over other kinases, and brain penetration. Here, we report a novel chemical series discovered through iterative core enumeration and decoration guided by free energy perturbation calculations. Type-III inhibitor

Indexed as

ADME propertiesc-MET inhibitorcore identificationfree energy perturbation

Identifiers

PMID42305208
PMCPMC13266642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.